外科 - dose - dense - EC - 乳腺 - q2w
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor - ScienceDirect
Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer - Cancer Therapy Advisor
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - ScienceDirect
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Current status of dose-dense chemotherapy for breast cancer | SpringerLink
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - ScienceDirect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
